-
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.
-
Migraine is associated with multiple disorders, including irritable bowel syndrome, restless legs syndrome, and non-alcoholic fatty liver disease. Understanding how these disparate disorders link to migraine may lead to an increased understanding of the pathogenesis of this complex neurological condition.
-
Interpret the ECG in the Figure obtained from a patient with new-onset chest pain. Localize the area(s) of acute infarction. Which coronary artery is likely to be acutely occluded?
-
Pain and Fall Risk Assessment in Cognitively Impaired Nursing Home Residents; PSA Screening: Maybe You Saw the Movie NeverEnding Story?; Screening for Lung Cancer in Asbestos Workers
-
The FDA has approved the first free fatty acid form of omega-3. Previous formulations have been ethyl esters of omega-3-acids. The omega-3-carboxylic acid is a fish oil-derived mixture of 50-60% eicosapentaenoic acid (EPA) and 15-25% docosahexaenoic acid (DHA) along with other potentially active omega-3 fatty acids. It is marketed by AstraZeneca as Epanova.
-
Severe obstructive sleep apnea is associated with a 30% increase in risk of incident diabetes, controlling for multiple relevant confounders.
-
In a study of vulnerable elderly population at risk for disability, a structured, moderate-intensity physical activity program compared with a health education program significantly reduced major mobility disability.
-
Administration of aspirin before surgery and throughout the early postsurgical period had no significant effect on the rate of composite of death or nonfatal myocardial infarction but did increase the risk of major bleeding.
-
In a study of primary care patients, primary nonadherence was found to be common and may be improved by eliminating cost barriers as well as more frequent physician visits.
-
The authors concluded that more than one of five simple risk factors for death would be an indication to explore advanced therapies in systolic HF patients < 80 years of age.